Close Menu


A deal with Burning Rock will allow the test to be used in trials and clinics in China, and Myriad will license its technology to French and German pathology labs.

In a study involving 1,300 blood samples from pregnant women, Myriad researchers demonstrated that their method could increase the fetal fraction for almost all.

Revenues and earnings were down year over year, but the company still beat the consensus Wall Street estimates on the top and bottom lines.

News items for the in vitro diagnostics industry for the week of Oct. 12, 2020.

Myriad Genetics' EndoPredict, Agendia's MammaPrint (distributed in Germany by PathoNext), and Veracyte's Prosigna will now be covered by public insurance.

As government lab spending grows, the Medicare contractor has barred access to a coding and pricing file obtained via FOIA claiming it holds business secrets.

News items for in vitro diagnostics industry for the week of August 17, 2020.

The firm reported total revenues of $93.2 million, down from $215.4 million in fiscal Q4 2019 and short of the consensus Wall Street estimate of $93.9 million.

In a local coverage article, Medicare contractors in the MolDx program added prostate cancer to the covered indications for the test.

News items for the in vitro diagnostics industry for the week of July 6, 2020